Non-Core Brands Downside Contribute to ANI Pharma's (ANIP) Revenue Miss; Roth Capital Reiterates Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to Non-Core Brands Downside Contribute to ANI Pharma's (ANIP) Revenue Miss; Roth Capital Reiterates Buy
November 3, 2015 9:14 AM EST
ANI Pharma (NASDAQ: ANIP) reported Q3 EPS of $0.80, $0.17 better than the analyst estimate of $0.63. Revenue for the quarter came in at $20 million versus the consensus estimate of $21.37 million.
ANI Pharma sees Q4 2015 EPS of $0.60-$0.76, versus the consensus of $0.70. ANI Pharma sees Q4 2015... More
November 2, 2015 2:23 PM EST
The Trading Radar highlights key earnings and economic announcements for the next trading session:
Before Markets Open:
Earnings:
1-800-FLOWERS.com (Nasdaq: FLWS) - consensus loss $0.26
ALLETE, Inc. (NYSE: ALE) - consensus EPS $1.00
AMAG Pharma (Nasdaq: AMAG) - consensus EPS $1.21
ANI Pharma (Nasdaq: ANIP) - consensus EPS $0.63
ARIAD Pharma0 (Nasdaq: ARIA) - consensus loss $0.23
Aircastle Limited (NYSE: AYR) - consensus EPS... More
November 2, 2015 8:22 AM EST
ANI Pharma (NASDAQ: ANIP) announced the launch of Vancomycin HCl 125mg and 250mg capsules indicated for treatment of C. difficile-associated diarrhea. The overall US market for Vancomycin HCl Capsules is approximately $113 million, per IMS Health.
Arthur S. Przybyl, President and Chief... More
